FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HERSHBERG ROBERT</u>						2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]									all application	all applicable) Director		g Person(s) to Issuer 10% Owner	
(Last) C/O AD SUITE 2	APTIVE BI	irst) OTECHNOLOG	(Middle) GIES COR	P.	02/	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2021									below)	(give title		Other (s below)	
(Street) SEATTL (City)	E W	tate)	98102 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filine) X Form filed by One Filed by More to Person											Repo		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code	3. 4 Transaction Code (Instr.		f, or Be ies Acquire Of (D) (Ins	d (A) or	5. Amou 4 and 5) Securitie Beneficia Owned F		s ally ollowing	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
							Code	v	Amount	(A) or (D) Pri			Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
Common Stock				02/14/2021		1			A		1,504	1,504 A		00	1,504			D	
Common Stock				02/16	16/2021				M ⁽¹⁾		2,000 A		\$0.	45	3,504		D		
Common Stock 02				02/16	6/202	5/2021		S ⁽¹⁾		2,000 D \$		\$65	.45	5 1,504			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, 1	4. Fransac Code (II		Derivative E		6. Date E Expiratio (Month/I	on Dat		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		D S (I	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amour or Number of Shares	er	Trans (Instr		U.II(3)		
Stock Option (Right to Buy)	\$66.5	02/14/2021			A		3,759		(2)		02/14/2031	Common Stock	3,759	9	\$0.00	3,759)	D	
Stock Option (Right to Buy)	\$0.45	02/16/2021		1	M ⁽¹⁾			2,000	(3)		02/04/2023	Common Stock	2,000	0	\$0.00	55,000	0	D	

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.
- 2. The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.
- 3. The option is fully vested and exercisable.

Remarks:

/s/ Robert Hershberg by Eric Billings, attorney-in-fact

02/17/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.